Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Venetoclax
Drug ID BADD_D02345
Description Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022]. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax [A40022]. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022]. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion [F2130].
Indications and Usage For the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
Marketing Status Prescription
ATC Code L01XX52
DrugBank ID DB11581
KEGG ID D10679
MeSH ID C579720
PubChem ID 49846579
TTD Drug ID Not Available
NDC Product Code 68513-0566; 0074-0576; 68513-0561; 54893-0090; 68543-0576; 71796-008; 0074-0579; 68513-0576; 0074-0566; 0074-0561; 46708-920
Synonyms venetoclax | 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide | benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)- | GDC-0199 | RG-7601 | RG7601 | ABT-199 | Venclexta
Chemical Information
Molecular Formula C45H50ClN7O7S
CAS Registry Number 1257044-40-8
SMILES CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C =C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic lymphocytic leukaemia recurrent16.01.06.003; 01.10.06.0030.000799%Not Available
Chronic lymphocytic leukaemia refractory16.01.06.004; 01.10.06.0040.000278%Not Available
Full blood count abnormal13.01.07.0030.000533%Not Available
Full blood count decreased13.01.07.004--Not Available
Haemosiderosis14.13.03.004; 12.02.08.0070.000533%Not Available
Mantle cell lymphoma refractory01.15.05.003; 16.28.05.0030.000139%Not Available
Monoclonal immunoglobulin present13.06.05.0130.000533%Not Available
Terminal state08.01.03.0790.000799%Not Available
Anaemia of malignant disease01.03.04.0030.000533%Not Available
Clostridium difficile infection11.02.02.0090.000533%Not Available
Biliary dilatation09.02.03.0040.000533%Not Available
Chronic lymphocytic leukaemia transformation16.01.06.005; 01.10.06.0050.000486%Not Available
Richter's syndrome16.28.02.005; 01.15.02.0050.002849%Not Available
General physical condition abnormal13.15.01.0400.000533%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.001042%Not Available
Scedosporium infection11.03.05.0290.000533%Not Available
Neutrophil count abnormal13.01.06.0180.001066%Not Available
Blast cell count increased13.01.03.0080.000278%Not Available
Multimorbidity08.01.03.0750.000208%Not Available
Lower respiratory tract infection fungal22.07.08.005; 11.03.05.0140.000139%Not Available
Apparent death08.01.03.0620.000533%Not Available
Oncologic complication16.32.03.0250.000139%Not Available
Subretinal fluid12.01.04.031; 06.09.03.0270.000533%Not Available
Refractory cancer16.16.01.0160.000139%Not Available
Bone marrow infiltration01.05.01.0180.000208%Not Available
Blastic plasmacytoid dendritic cell neoplasia23.07.04.021; 16.20.01.004; 01.12.01.0040.000278%Not Available
The 12th Page    First    Pre   12    Total 12 Pages